|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-19.20/-5.86
|
企業價值
7.13M
|
資產負債 |
每股賬面淨值
0.68
|
現金流量 |
現金流量率
--
|
損益表 |
收益
0
|
每股收益
0.73
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/19 07:26 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection. |